In the wave of digital transformation, the healthcare industry is undergoing profound changes. Recently, the third Binhai Zhongguancun Collaborative Innovation Development Exchange Conference was grandly held in Beijing with the theme "Collaborative Innovation, Intelligent Future," gathering numerous industry leaders and innovators. In this feast of ideas, Dr. Xu Juan, Vice President of DHC and Dean of the Artificial Intelligence Research Institute, was invited to attend. During the roundtable discussion on "Digital Empowerment Drives the Development of the Life Health Industry," she shared her profound insights and valuable experiences based on DHC's achievements in the field of medical artificial intelligence, attracting widespread attention from guests and audience members at the event. 

"Data standardization and cross-modal data governance are the cornerstones of medical AI development," emphasized Dr. Xu Juan. These practices provide a solid foundation for AI research and clinical applications. Taking the "China Kidney Disease Big Data Platform," jointly established by the National Clinical Research Center for Kidney Diseases and the Chinese Center for Disease Control and Prevention's Chronic Non-communicable Disease Prevention and Control Center, as an example, DHC provides exclusive big data and AI technical support for the platform. The platform integrates cases from 50 million patients, forming a closed loop of data integration-governance-analysis, which offers scientific decision support for chronic kidney disease prevention strategies and diagnostic models, further enhancing the research level of hospitals and kidney disease studies nationwide, and promoting high-quality development in China's kidney disease discipline. DHC's large model, based on multimodal big data technology, plays a crucial role in clinical decision support and medical research scenarios. Dr. Xu Juan introduced that DHC independently developed a multimodal large model supported by four major modality base models—text, imaging, pathology, and precision—relying on AI technology and high-quality multimodal big data. It integrates and analyzes various sources of data such as clinical texts, medical images, pathological data, and genetic data, creating a multimodal intelligent system specific to the medical field.

In terms of clinical decision support, DHC's large model not only provides doctors with deeper insights and recommendations, assisting in disease diagnosis and personalized treatment plans but also predicts patient outcomes, recurrence, and metastasis risks, offering timely intervention measures and treatment advice. Moreover, by connecting patients' diagnostic information through the big data platform, it achieves comprehensive digitalization of patient characteristics, supporting individualized diagnostic services and lifestyle health advice. In medical research, DHC's large model also shows great potential. It can efficiently process and analyze vast amounts of medical literature, clinical trial data, and biomarker information, helping researchers quickly identify key issues and trends in their fields, foster new hypotheses generation and validation, thereby driving innovation and expansion of medical knowledge. Aiming to form a new paradigm for data-intensive medical research based on data integration, AI technology, and clinical research goals, it seeks to occupy a new high ground in medical research, gradually promoting the clinical application transformation of multimodal technology, and achieving digital precision diagnosis and treatment. Currently, it has co-established the first large model-assisted whole-hospital multimodal data governance system with Nanfang Hospital of Southern Medical University and supported Chongqing University Cancer Hospital in building the first large model-supported intelligent oncology knowledge base in China.

From medical datafication to digitalization, and then to intelligence, DHC has always been at the forefront of technological progress, driving the development of the healthcare industry and continuously providing innovative technical support and mature practical experience for the digital transformation and intelligent upgrade of the healthcare industry. With continuous technological advancements and expanding application fields, DHC will continue to bring more surprises and value to the healthcare industry with its outstanding technical strength and innovative spirit, providing more efficient work support for medical professionals, higher quality medical services for patients, and greater health value for society as a whole. 

About Xu Juan Xu Juan, Vice President of DHC and Dean of the Artificial Intelligence Research Institute, holds a Bachelor's degree in Electronics from Peking University and a Ph.D. in Biomedical Engineering from Nanyang Technological University, Singapore. With 20 years of deep involvement in the intersection of medicine and computer science, she has extensive experience in constructing multimodal medical big data platforms using cutting-edge technologies, specializing in multidimensional integration, data modeling, intelligent analysis, and clinical application of complex health care data. She has served as an Assistant Researcher at the University of Pittsburgh Medical Center (UPMC), a Senior Researcher at Siemens Research Institute, and Director of the Artificial Intelligence Innovation Laboratory at Ali Health Smart Medical Business Department. She has applied for over 40 international and domestic invention patents and published 55 papers in international journals and conferences.